Experience
Patent counsel to clinical stage pharmaceutical company on all aspects of patent strategy and portfolio development for small molecule pipeline, including advising on IP due diligence for strategic funding collaborations and licensing agreements worth over $500 million.
Patent counsel to Aurinia Pharmaceuticals for LUPKYNIS®, the first FDA-approved oral treatment specifically for lupus nephritis.
Patent counsel to Seagen on global portfolio for antibody-drug conjugate (ADC) pipeline candidates, platform technologies, and marketed therapeutics.
Patent counsel to UCB, a global biopharmaceutical company, on clinical-stage program for treatment of Parkinson’s disease.
Patent counsel to Frontier Medicines, a clinical stage precision medicine company advancing treatments for genetically-defined patient populations in oncology and immunology, on all aspects of patent strategy and portfolio development for pipeline of small molecule therapeutics.
Patent counsel to Cerus on patent portfolio development for their pathogen-protected blood components, including the INTERCEPT® Blood System.
Advised General Catalyst on IP due diligence for various transactions, including investment in $72 million Series A funding round of Maxion Therapeutics, developer of drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, and $155 million Series B funding round of ArriVent Biopharma, developer of pharmaceutical products intended to cure presently untreatable cancer.
Advised Frazier Life Sciences in IP due diligence for launch of Callio Therapeutics, which included $187 million in series A funds for development of dual-payload antibody-drug conjugates (ADCs) for treatment of cancer.
Advised Abingworth on IP due diligence for $150 million strategic development funding agreement with Teva for development of dual-action asthma rescue inhaler respiratory program.